| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_421cc1bbebbd183600236139908dacaa |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M31-002 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 |
| filingDate |
2020-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75b9079ec08284078f621fdf43afeaad |
| publicationDate |
2022-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022280503-A1 |
| titleOfInvention |
Compositions of opioid antagonists, implant devices, and treatment methods for opioid use disorder |
| abstract |
Compositions comprising a formulation of an opioid antagonist and an organic acid are described. The opioid antagonist is a base and has a water solubility at room temperature of less than about 1.0 g/L. The organic acid is combined with the opioid antagonist in a mole ratio less than or equal to 1:1 (acid:drug), has a water solubility at room temperature of between 0.1 and 10 g/L, and/or has a molar mass of less than 400 grams per mole. The organic acid enhances the solubility of the opioid antagonist, and thus facilitates the release of the opioid antagonist into a buffered environment of use for prolonged periods of, for example, six months to one year. Diffusion-based drug delivery devices comprising the compositions and methods of treatment are also described. |
| priorityDate |
2019-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |